Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 285
- Registration Number
- NCT05584670
- Locations
- 🇳🇱
Erasmus MC_Investigational Site Number : 5280003, Rotterdam, Netherlands
🇮🇱Sheba Medical Center - PPDS_Investigational Site Number : 3760003, Ramat Gan, Israel
🇺🇸John Theurer Cancer Center Site Number : 8400001, Hackensack, New Jersey, United States
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05497336
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- D3 Bio (Wuxi) Co., Ltd
- Target Recruit Count
- 392
- Registration Number
- NCT05410145
- Locations
- 🇪🇸
D3 Bio Investigative Site, Valencia, Spain
A Study of ASP3082 in Adults With Advanced Solid Tumors
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 541
- Registration Number
- NCT05382559
- Locations
- 🇺🇸
Florida Cancer Specialist, Lake Mary, Florida, United States
🇺🇸Case Western, Cleveland, Ohio, United States
🇺🇸University of Wisconsin Hospital, Madison, Wisconsin, United States
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 346
- Registration Number
- NCT05358249
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸NYU School of Medicine, New York, New York, United States
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- Conditions
- Interventions
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 156
- Registration Number
- NCT05355701
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸Clinical and Translational Research Center (CTRC), Aurora, Colorado, United States
🇺🇸Clinical And Translational Research Center, Aurora, Colorado, United States
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
- Conditions
- Interventions
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 219
- Registration Number
- NCT05312398
- Locations
- 🇮🇹
A.O.U. Ospedali Riuniti, Ancona, AN, Italy
🇮🇹A.O.U. Cagliari - Presidio Policlinico D. Casula, Monserrato, CA, Italy
🇮🇹Ospedale Sacro Cuore di Gesù - FATEBENEFRATELLI, Benevento, BN, Italy
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 84
- Registration Number
- NCT05308446
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸Mercy Cancer Center - Carmichael, Carmichael, California, United States
CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 173
- Registration Number
- NCT05291156
- Locations
- 🇮🇹
A.O.U. Ospedali Riuniti, Ancona, Italy
🇮🇹A.O. San Giuseppe Moscati, Avellino, Italy
🇮🇹Centro di Riferimento Oncologico (C.R.O.), Aviano, Italy
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- BioAtla, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05271604
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Christiana Care Helen Graham Cancer Center, Newark, Delaware, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.